EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Bayesian analysis of the Substrate Ablation vs. Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia trial

Pablo Ávila iD, Antonio Berruezo iD, Javier Jiménez-Candil iD, Luis Tercedor iD, David Calvo iD, Fernando Arribas iD, Javier Fernández-Portales iD, José Luis Merino iD, Antonio Hernández-Madrid, Francisco Fernández-Avilés iD, Ángel Arenal iD

Europace · 2023

DOI: 10.1093/europace/euad181 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Europace, 2023. Verfasst von Pablo Ávila und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Department, Hospital General Universitario Gregorio Marañón, IiSGM, Universidad Complutense, CIBERCV, Dr Esquerdo 46, 28007, Madrid, Spain. Hauptthemen laut MEDLINE: Cardiomyopathies, Catheter Ablation, Defibrillators, Implantable, Myocardial Ischemia. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, European Regional Development Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aims Bayesian analyses can provide additional insights into the results of clinical trials, aiding in the decision-making process. We analysed the Substrate Ablation vs. Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia (SURVIVE-VT) trial using Bayesian survival models. Methods and results The SURVIVE-VT trial randomized patients with ischaemic cardiomyopathy and monomorphic ventricular tachycardia (VT) to catheter ablation or antiarrhythmic drugs (AAD) as a first-line strategy. The primary outcome was a composite of cardiovascular death, appropriate implantable cardioverter–defibrillator shocks, unplanned heart failure hospitalizations, or severe treatment-related complications. We used informative, skeptical, and non-informative priors with different probabilities of large effects to compute the posterior distributions using Markov Chain Monte Carlo methods. We calculated the probabilities of hazard ratios (HR) being <1, <0.9, and <0.75, as well as 2-year survival estimates. Of the 144 randomized patients, 71 underwent catheter ablation and 73 received AAD. Regardless of the prior, catheter ablation had a >98% probability of reducing the primary outcome (HR < 1) and a >96% probability of achieving a reduction of >10% (HR < 0.9). The probability of a >25% (HR < 0.75) reduction of treatment-related complications was >90%. Catheter ablation had a high probability (>93%) of reducing incessant/slow undetected VT/electric storm, unplanned hospitalizations for ventricular arrhythmias, and overall cardiovascular admissions > 25%, with absolute differences of 15.2%, 21.2%, and 20.2%, respectively. Conclusion In patients with ischaemic cardiomyopathy and VT, catheter ablation as a first-line therapy resulted in a high probability of reducing several clinical outcomes compared to AAD. Our study highlights the value of Bayesian analysis in clinical trials and its potential for guiding treatment decisions. Trial Registration ClinicalTrials.gov identifier: NCT03734562

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CardiomyopathiesCatheter AblationDefibrillators, ImplantableMyocardial IschemiaTachycardia, VentricularHumansAnti-Arrhythmia AgentsBayes TheoremTreatment Outcome

Stichwörter der Autor:innen

Anti-arrhythmic drugsBayesian analysisCatheter ablationVentricular tachycardia

Substanzen

Anti-Arrhythmia Agents

Autor:innen und Institutionen

  • Cardiology Department, Hospital General Universitario Gregorio Marañón, IiSGM, Universidad Complutense, CIBERCV, Dr Esquerdo 46, 28007, Madrid, Spain.
  • Arrhythmia Unit, Cardiology Department, Hospital Clinic and Teknon Medical Centre, c/Villarroel 170, 08036, Barcelona, Spain.
  • Arrhythmia Unit, Cardiology Department, IBSAL-Hospital Universitario, Universidad de Salamanca, CIBERCV, Paseo San Vicente 58-182, 37007, Salamanca, Spain.
  • Arrhythmia Unit, Cardiology Department, Hospital Universitario Virgen de las Nieves, Avd. Fuerzas Armadas 2, 18014, Granada, Spain.
  • Arrhythmia Unit, Cardiology Department, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Avd Roma, s/n, 33011, Oviedo, Spain.
  • Arrhythmia Unit, Cardiology Department, Hospital Clínico San Carlos, Prof Martín Lagos, S/N, Madrid, 28040, Spain.

ORCID-Profile: Pablo Ávila, Antonio Berruezo, Javier Jiménez-Candil, Luis Tercedor, David Calvo, Fernando Arribas, Javier Fernández-Portales, José Luis Merino, Francisco Fernández-Avilés, Ángel Arenal

Förderung

  • Instituto de Salud Carlos III
  • Ministerio de Ciencia e Innovación
  • European Regional Development Fund
  • Biosense Webster

Zitieren

APA

Ávila, P., Berruezo, A., Jiménez-Candil, J., Tercedor, L., Calvo, D., Arribas, F., Fernández-Portales, J., Merino, J. L., Hernández-Madrid, A., Fernández-Avilés, F., & Arenal, Á. (2023). Bayesian analysis of the Substrate Ablation vs. Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia trial. Europace. https://doi.org/10.1093/europace/euad181

Vancouver

Ávila P, Berruezo A, Jiménez-Candil J, Tercedor L, Calvo D, Arribas F, et al. Bayesian analysis of the Substrate Ablation vs. Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia trial. Europace. 2023. doi:10.1093/europace/euad181

BibTeX
@article{vila2023,
  author = {Ávila, Pablo and Berruezo, Antonio and Jiménez-Candil, Javier and Tercedor, Luis and Calvo, David and Arribas, Fernando and Fernández-Portales, Javier and Merino, José Luis and Hernández-Madrid, Antonio and Fernández-Avilés, Francisco and Arenal, Ángel},
  title = {Bayesian analysis of the Substrate Ablation vs. Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia trial},
  journal = {Europace},
  year = {2023},
  doi = {10.1093/europace/euad181}
}
Kostenlos starten →